NCT05149326进行中（未招募）3 期
A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 408
- 试验地点
- 65
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18, male or female;
- •Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);
- •Has not received prior systemic treatment for their locally advanced or metastatic PDAC;
- •Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1);
- •Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;
- •Has a life expectancy of at least 3 months;
- •Has adequate organ function;
- •If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;
- •If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.
排除标准
- •Untreated active CNS metastasis or leptomeningeal metastasis.
- •Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;
- •Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment;
- •Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and/or if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;
- •Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment;
- •Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to < 10 mg prednisone daily, inhaled steroids and topical use of steroids);
- •Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines);
- •Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;
- •History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent；
- •Previous malignant disease History of uncontrolled intercurrent illness Prior therapy with any antibody/drug targeting T cell coregulatory proteins Known severe hypersensitivity reactions to antibody drug；
- •Is pregnant or breastfeeding;
- •Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.
研究组 & 干预措施
Experimental arm
Experimental
干预措施: KN046 (Drug)
Control arm
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: up to 2 years
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up.
次要结局
- Progression-free survival (PFS)(up to 2 years)
- Overall response rate (ORR)(up to 2 years)
研究者
研究点 (65)
Loading locations...
相似试验
已完成
3 期
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLCExtensive Stage Small Cell Lung CancerNCT04063163Shanghai Henlius Biotech585
进行中（未招募）
3 期
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04974398Akeso296
进行中（未招募）
3 期
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCSquamous Non Small Cell Lung CancerNCT04033354Shanghai Henlius Biotech537
尚未招募
3 期
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT06492941CSPC ZhongQi Pharmaceutical Technology Co., Ltd.142
进行中（未招募）
3 期
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Esophageal Squamous Cell CarcinomaNCT03958890Shanghai Henlius Biotech489